| My Account | Subscribe | Contact Us | Donate |
Home
- The Edmonton Protocol and Me
- Olympia Dukakis and Her Husband Tackle Type 2
- Surfing with Type 1
- Behind the Wheel, But Still in Control
You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
If you are a physician, educator and medical professional who focus on the treatment of diabetes, then this is the must have resource for you.
Finally! A fresh take on the “professional” journal. Each bi-monthly issue cuts through the jargon and presents the most important information you need to enhance your practice and assist your patients.
Each bi-monthly issue of Diabetes Health Professional is a self-contained handbook covering products, educational resources and the latest diabetes research, complimented by balanced editorial focused on medical news, drug prescription information, clinical practice recommendations and changing treatment options.
Each quarter we send you the latest, most updated research guides, product guides and educational resource guides available for you and your patients.
Each week the Diabetes Health E-Newsletter delivers links to the very latest in news, reviews, blogs and videos from Diabetes Health direct to your inbox.
As a subscriber you'll get access to the amazing Diabetes Health Digital Advantage™ so you can read the current issue of Diabetes Health magazine online wherever you are!
You can cancel your newsletter subscription at anytime by clicking "Unsubscribe" on the bottom of any newsletter you receive
Then enter your new email address in the above form and click "Subscribe"
Latest Pharmacy Articles
No effect on bone density among men was seen in any of the studies the researchers analyzed.
Women Have Double the Fracture Risk with Avandia and Actos
Avandia (rosiglitazone) and Actos (pioglitazone), two medications used to lower blood sugar in type 2 patients, double the risk of fractures in women, but not in men, says a new study.
"Women who are taking these drugs should reconsider the options," said lead researcher Dr. Yoon Loke, a clinical senior lecturer at the University of East Anglia in Norwich, in a recent press release.
About 4 million people in the United States take these drugs, which are in a class called thiazolidinediones. Recent studies have also suggested that Avandia increases the risk for heart failure, death, and heart attack, findings that have resulted in new FDA-ordered warning labels about the drug.
Loke's team evaluated 10 trials that included 13,715 diabetics taking Avandia, Actos, or neither. They found that the two drugs reduced bone density in the spine and hips. According to their estimates, this loss of bone density doubles the risk of fractures in women taking either drug.
No effect on bone density among men was seen in any of the studies the researchers analyzed.
Loke speculated in the press release that women are affected because of an interaction between the drugs and estrogen, which weakens bones in women.
GlaxoSmithKline, the maker of Avandia, said in a press release that this study merely reiterates information that is already known and printed on Avandia's label.
Source: HealthDay
Categories: Actos, Heart Care & Heart Disease, Medications, Medications Research, Pharmacy, Sexual Issues, Type 2 Issues
Facebook
MySpace 
Digg
You May Also Be Interested In...
Click Here To View Or Post Comments
0 comments -
Dec 22, 2008 -
Email to a Friend
Send a link to this page to your friends and colleagues.